TheBodyPro | Expert analysis from Benjamin Young, M.D., Ph.D.
At the moment, we have only one complete, long-acting antiretroviral regimen approved for HIV treatment in the U.S.: cabotegravir/rilpivirine. But new findings out of San Francisco give us reason to start thinking about an off-label switch strategy involving a pair of injectables that are rarely co-prescribed: cabotegravir plus lenacapavir.
Investigators conducted a retrospective case series by reviewing electronic medical records for people receiving long-acting lenacapavir with cabotegravir, with or without rilpivirine, at the Ward 86 HIV Clinic at San Francisco General Hospital. The time period for patient inclusion spanned from March 2023 to May 2025, although follow-up extended through November 2025, with clinician verification of the clinical data.
The study assessed viral suppression, defined as an HIV RNA level below 200 copies/mL. The study assessed viral outcomes and adverse effects during follow-up.
Read the full analysis here.
Further reading on long-acting antiretrovirals:
- Managed Healthcare Executive | Long-acting lenacapavir plus cabotegravir kept all 46 patients with HIV virally suppressed in recent trial
- POZ | Long-acting injectables may be an option for people without viral suppression
- MedPage Today | Long-acting HIV shot works just fine for patients with adherence issues
Source : TheBodyPro
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.